Compare BKTI & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BKTI | ALDX |
|---|---|---|
| Founded | 1997 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 244.2M | 293.0M |
| IPO Year | N/A | 2014 |
| Metric | BKTI | ALDX |
|---|---|---|
| Price | $87.57 | $4.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $74.00 | $9.50 |
| AVG Volume (30 Days) | 44.2K | ★ 860.5K |
| Earning Date | 11-06-2025 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 136.69 | N/A |
| EPS | ★ 3.30 | N/A |
| Revenue | ★ $82,558,000.00 | N/A |
| Revenue This Year | $12.00 | N/A |
| Revenue Next Year | $11.30 | $36.25 |
| P/E Ratio | $26.34 | ★ N/A |
| Revenue Growth | ★ 10.12 | N/A |
| 52 Week Low | $26.20 | $1.14 |
| 52 Week High | $89.23 | $7.20 |
| Indicator | BKTI | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 72.51 | 51.82 |
| Support Level | $75.20 | $3.95 |
| Resistance Level | $89.23 | $4.33 |
| Average True Range (ATR) | 3.83 | 0.29 |
| MACD | 0.99 | 0.00 |
| Stochastic Oscillator | 89.00 | 57.14 |
BK Technologies Corp a holding company, operates through its subsidiary, BK Technologies, Inc., specializing in designing, manufacturing, and marketing wireless communications equipment. Its Radio business unit offers two-way land mobile radios (LMRs) serving government and public safety markets, as well as industrial and commercial enterprises. The SaaS business unit focuses on public safety smartphone applications, enhancing first responders' safety and efficiency. The BKRplay application, tethered to BK radios, amplifies user capabilities, expanding the reach of their radio sales. Its product portfolio consists of two-way land mobile radios, handheld radios, radios installed in vehicles.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.